Sanara MedTech news

Under investigation for potential securities law violations and fiduciary duty breaches related to its acquisition by MiMedx Group, raising questions about deal fairness and shareholder protection.

Company is under investigation for potential securities law violations and breach of fiduciary duties related to its acquisition by MiMedx Group, with concerns about whether shareholders are receiving fair consideration.

Under investigation for potential breach of fiduciary duties regarding acquisition by MiMedx Group at $35 per share; concerns raised about fair process and fair value to shareholders

Company exceeded Q1 expectations with 19% revenue growth, achieved GAAP profitability after prior losses, improved gross margins by 100 basis points to 93%, expanded sales team to 43 reps, increased facility penetration to 1,400+ locations, paid debt service entirely in cash for the first time, and maintained confident full-year guidance of 13-17% growth. Strong execution on strategic shift to pure-play surgical focus and positive momentum heading into Q2.

The company is under investigation for issuing false or misleading statements regarding the discontinuation of a major program. The announcement resulted in a significant 24.7% stock price decline and a substantial $31.2 million loss from discontinued operations, indicating serious operational and financial issues.

Being acquired by MIMEDX in a described 'transformational combination' suggests value creation and strategic alignment. The acquisition is positioned as beneficial for expanding regenerative medicine capabilities across surgical subspecialties.